<DOC>
	<DOCNO>NCT02230696</DOCNO>
	<brief_summary>To compare safety efficacy Perrigo 's steroid drug product compare FDA approve steroid drug product treatment subject seasonal allergic rhinitis .</brief_summary>
	<brief_title>Comparative Safety Efficacy Two Steroid Treatments Relief Symptoms Seasonal Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<criteria>1 . Complete inform consent/assent process . 2 . Male female 12 65 year age , inclusive . 3 . Females childbearing potential willing use acceptable form birth control study . 4 . Moderatetosevere allergic rhinitis . 5 . At Visits 1 2 instantaneous reflective symptom score sufficient enough qualify continued participation study 6 . Subject must history ( 2 season ) seasonal allergy least one allergen know present study season . 7 . Subject must general good health clinically significant disease medical procedure allergic rhinitis within various time period prior Visit 1 . 8 . Subject must willing able understand comply requirement study 1 . Female pregnant nursing , use agree use acceptable form contraception study , intend become pregnant study . 2 . Subject history hypersensitivity allergy ingredient drug product . 3 . Subject condition abnormality upper airway , opinion Investigator , could interfere administration product , evaluation subject 's condition , aspect trial . 4 . The presence nasal mucosal crusting , erosion , ulceration , nasal septum perforation , kind blockage nasal passages screen randomization . 5 . Subject asthma history asthma require chronic treatment within two year Visit 1 . 6 . Treatment oral Candidiasis within 30 day start study , current oral Candidiasis infection . 7 . Subject recent exposure ( 30 day ) risk expose chicken pox measles . 8 . Subjects untreated fungal , bacterial , systemic viral infection within previous 30 day . 9 . Use various therapy within give time period prior Visit 1 throughout study . 10 . Initiation hormone replacement therapy study . 11 . Initiation immunotherapy study , change dosage frequency immunotherapy within 30 day precede Visit 1 . 12 . Subject receive immunesystem therapy peptide immunotherapy form . 13 . Subject desensitization therapy seasonal allergen cause allergic rhinitis within previous 6 month . 14 . Subject present conjunctivitis eye signs/symptoms related diagnosis SAR . 15 . Clinically relevant abnormal physical finding medication use within 1 week randomization , , opinion investigator , might interfere conduct result study place prospective subject increase risk . 16 . Subjects treat product contain sympathomimetic agent . 17 . Subject previously enrol study enrol study another participate investigator site . 18 . Subject concurrently participate another investigational study use investigational drug ( biologic ) device . 19 . Subject plan anticipate travel outside local allergen area point study . 20 . History unresponsiveness steroid nasal spray SAR symptom . 21 . Employee ( employee 's family member ) research center private practice . 22 . If subject smoke history great 10 pack year recently start restarted smoking within past 2 year</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>